Back to Results

Biodexa Pharmaceuticals PLC DRC (BDRX)

Biodexa Pharmaceuticals PLC DRC is a NASDAQ-listed depositary receipt representing common stock of Biodexa Pharmaceuticals Plc, a UK-based biopharmaceutical company focused on clinical-stage development programs. The company is working on treatments for familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and selected rare cancers, including brain tumors. Its lead candidate, Tolimidone, is being evaluated in Phase II studies for Type 1 diabetes. Biodexa is also advancing MTX110 in early-stage trials for diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition to its drug candidates, the company has developed platform technologies including Q-Sphera, MidaSolve, and MidaCore. It has collaboration agreements with Janssen and Melior. The company, formerly Midatech Pharma plc, adopted the Biodexa Pharmaceuticals Plc name in March 2023 and is headquartered in Cardiff, United Kingdom.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BDRX
$0.93
36.3% Upside
Undervalued
$8.98 1,218.8% Upside
Not available
Bargain
Weak
0.0%
December 11, 2026
0.1x
700.793 K
-3.565 M
0.0%
91.7%
-75.1
156.2%
Valuation • Fair Value

Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) Fair Value by Valuation Model

Review the available estimates for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.93

Estimated upside of 36.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.93

Comparable-company valuation reference.

Analyst Price Target

$8.98 1,218.8% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-11.735 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-75.1

Lower score that deserves closer risk review.

FCF / Net Income

156.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 11, 2026

Days to Earnings

80

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) Stock FAQ

Data-supported answers about Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.93
Estimated upside 36.3%
Valuation Rating
Undervalued
Estimated upside of 36.3%
Analyst Target
$8.98 1,218.8% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is $0.93. This implies an estimated upside of 36.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 36.3% versus the current market price.

The available analyst price target for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is $8.98 1,218.8% Upside.

The current financial health read for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is December 11, 2026.

The latest available data indicates no current dividend yield for Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX).

The current market capitalization listed for Biodexa Pharmaceuticals PLC DRC is 700.793 K.

The current enterprise value listed for Biodexa Pharmaceuticals PLC DRC is -3.565 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Biodexa Pharmaceuticals PLC DRC is NASDAQ-BDRX, and the stock is listed on NASDAQ.

Biodexa Pharmaceuticals PLC DRC (NASDAQ-BDRX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Biodexa Pharmaceuticals PLC DRC is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Biodexa Pharmaceuticals PLC DRC is 91.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B